Genenta Science (NASDAQ:GNTA)‘s stock had its “buy” rating restated by investment analysts at Roth Capital in a research note issued to investors on Wednesday, Zacks.com reports.
Separately, Maxim Group began coverage on Genenta Science in a research note on Thursday. They issued a “buy” rating and a $21.00 price objective for the company.
NASDAQ GNTA opened at $10.21 on Wednesday. Genenta Science has a one year low of $9.10 and a one year high of $13.13.
Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM). Genenta Science S.p.A. is based in MILAN, Italy.
See Also: What is a Market Correction?
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.